Boston Pharma hits phase 2 MASH goal, positioning monthly prospect to follow Akero, 89bio into pivotal trials

cafead

Administrator
Staff member
  • cafead   Nov 15, 2024 at 11:32: AM
via Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes in a midphase trial, positioning the biotech to advance the ex-Novartis candidate toward late-stage development in 2025.

article source